| [1] |
Osborne CK. Tamoxifen in the treatment of breast cancer [J]. N Engl J Med,1998,339(22):1609-1618.
|
| [2] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. breast cancer version 2.2016[EB/OL].[2016-08-28]. https:/ /www. nccn. org/professionals/physician _ gls/pdf/bladder.pdf.
|
| [3] |
Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2009,7(2):122-192.
|
| [4] |
Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer [J]. J Clin Oncol,2010,28(23):3784-3796.
|
| [5] |
Goldhirsch A,Winer EP,Coates AS,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J]. Ann Oncol,2013,24(9):2206-2223.
|
| [6] |
Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors [J]. N Engl J Med,1989,320(8):479-484.
|
| [7] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J]. Lancet,2011,378(9793):771-784.
|
| [8] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005,365(9472):1687-1717.
|
| [9] |
Jatoi I, Anderson WF, Jeong JH, et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects [J]. J Clin Oncol,2011,29(17):2301-2304.
|
| [10] |
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial [J]. Lancet Oncol,2010,11(12):1135-1141.
|
| [11] |
Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up [J].Lancet Oncol,2011,12(12):1101-1108.
|
| [12] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J]. Lancet,2013,381(9869):805-816.
|
| [13] |
Gray RG,Rea D,Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer [J]. J Clin Oncol, 2013,31(18):2631-2632.
|
| [14] |
Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [J]. N Engl J Med,2014,371(2):107-118.
|
| [15] |
Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA. 17 trial:analyses adjusting for treatment crossover [J]. J Clin Oncol, 2012,30(7):718-721.
|
| [16] |
Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a [J]. J Natl Cancer Inst,2007,99(24):1845-1853.
|
| [17] |
Goss PE, Ingle JN, Pritchard KI, et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer[EB/OL]. [2016-08-28]. http:/ /jco. ascopubs. org/cgi/content/abstract/34/18_suppl/LBA1.
|
| [18] |
Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial [J]. J Natl Cancer Inst,2001,93(9):684-690.
|
| [19] |
Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [J]. J Natl Cancer Inst,1996,88(24):1828-1833.
|
| [20] |
Sestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer [J]. J Natl Cancer Inst,2013,105(19):1504-1511.
|
| [21] |
Hongchao P, Gray RG, Davies C, et al. Predictors of recurrence during years 5-14 in 46 138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)[J]. J Clin Oncol,2016,34(suppl):505.
|
| [22] |
Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial [J]. J Clin Oncol,2008,26(7):1059-1065.
|
| [23] |
Adjuvant Inc. Adjuvant! Online [EB/OL]. [2016-08-28]. www.adjuvantonline.com/.
|
| [24] |
Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population[J]. Lancet Oncol,2013,14(11):1067-1076.
|
| [25] |
Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score [J]. J Clin Oncol,2015,33(8):916-922.
|
| [26] |
Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline [J]. J Clin Oncol,2016,34(10):1134-1150.
|
| [27] |
Paik S,Shak S,Tang G,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J]. N Engl J Med,2004,351(27):2817-2826.
|
| [28] |
王文彦,王昕,王阳,等.21 基因检测复发风险评分在早期乳腺癌中的临床分析[J/CD].中华乳腺病杂志(电子版),2015,9(1):30-34.
|
| [29] |
Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy [J]. J Natl Cancer Inst,2016,108(11): djw149.
|
| [30] |
Martin M, Brase JC, Calvo L, et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients:results from the GEICAM 9906 trial [J]. Breast Cancer Res,2014,16(2): R38.
|
| [31] |
Dubsky P, Filipits M, Jakesz R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ERpositive, HER2-negative early breast cancer [J]. Ann Oncol, 2013,24(3):640-647.
|
| [32] |
Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors [J]. Clin Cancer Res,2011,17(18):6012-6020.
|
| [33] |
No authors listed. Tamoxifen for early breast cancer:an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group[J]. Lancet,1998,351(9114):1451-1467.
|
| [34] |
Koornstra RH, Beelen KJ, Vincent AD, et al. St. Gallen endocrine response classes predict recurrence rates over time [J]. Breast,2015,24(6):705-712.
|
| [35] |
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010,28(16):2784-2795.
|
| [36] |
Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen [J]. J Clin Oncol,2008,26(12):1948-1955.
|
| [37] |
Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence [J]. J Clin Oncol,2016,34(21):2452-2459.
|